ABB Pharmaceuticals Limited - Period Ending 2016-06-30

ABB Pharmaceuticals Limited

Unaudited Abbreviated Accounts

Year Ended 30 June 2016

Page Kirk LLP
Chartered Accountants
Sherwood House
7 Gregory Boulevard
Nottingham
NG7 6LB

ABB Pharmaceuticals Limited
Contents

Accountants' Report

Abbreviated Balance Sheet

Notes to the Abbreviated Accounts

ABB Pharmaceuticals Limited
Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts Year Ended 30 June 2016

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of ABB Pharmaceuticals Limited for the year ended 30 June 2016 set out on pages 2 to 3 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW) , we are subject to its ethical and other professional requirements which are detailed at icaew.com/membershandbook .

This report is made solely to the Board of Directors of ABB Pharmaceuticals Limited , as a body, in accordance with the terms of our engagement letter dated 25 June 2010 . Our work has been undertaken solely to prepare for your approval the accounts of ABB Pharmaceuticals Limited and state those matters that we have agreed to state to them, as a body, in this report in accordance with AAF 2/10 as detailed at icaew.com/compilation . To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than ABB Pharmaceuticals Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that ABB Pharmaceuticals Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of ABB Pharmaceuticals Limited . You consider that ABB Pharmaceuticals Limited is exempt from the statutory audit requirement for the year .

We have not been instructed to carry out an audit or a review of the accounts of ABB Pharmaceuticals Limited . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Page Kirk LLP
Chartered Accountants
Sherwood House
7 Gregory Boulevard
Nottingham
NG7 6LB

17 March 2017

Page 1

ABB Pharmaceuticals Limited
Abbreviated Balance Sheet
30 June 2016

		Note		2016				2015
	£		£		£		£
Current assets
Debtors						-			22,000
Cash at bank and in hand						6,870			7,191
						6,870			29,191
Creditors: Amounts falling due within one year						(63,542)			(61,975)
Net liabilities						(56,672)			(32,784)
Capital and reserves
Called up share capital		2		52,000				52,000
Profit and loss account				(108,672)				(84,784)
Shareholders' deficit						(56,672)			(32,784)

For the year ending 30 June 2016 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These abbreviated accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 17 March 2017 and signed on its behalf by:

.........................................
Mr A S Burbage
DirectorCompany registration number: 07290804

The notes on page 3 form an integral part of these financial statements.
Page 2

ABB Pharmaceuticals Limited
Notes to the Abbreviated Accounts
Year Ended 30 June 2016

1	Accounting policies

Basis of preparation

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (Effective January 2015).This is the first year that the financial statements have been prepared in accordance with the FRSSE 2015. There are no material transitional adjustments.

Going concern

The company are in the process of developing products for eventual sale on the open market. The directors and related parties are supporting the company and undertake not to withdraw their loans for at least 12 months. As a result the company accounts are prepared on the going concern basis.

Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability in the balance sheet. The corresponding dividends relating to the liability component are charged as interest expense in the profit and loss account.

2	Share capital

Allotted, called up and fully paid shares

	2016			2015
		No.	£		No.	£
Ordinary of £1 each		52,000	52,000		52,000	52,000

Page 3